Compare Inovio Pharmaceuticals Inc (INO) vs Modine Manufacturing Company (MOD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Modine Manufacturing Company — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Modine Manufacturing Company trades at $242.6 (market cap $12.18B). The key difference: Modine Manufacturing Company is far larger — about 136.4× Inovio Pharmaceuticals Inc's market cap, and Modine Manufacturing Company is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | MOD | |
|---|---|---|
Market Cap | $89.27M | $12.18B |
Sector | Health | Technology |
52-Week High | $2.87 | $306.89 |
52-Week Low | $1.05 | $93.71 |
Enterprise Value | $60.28M | $12.54B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
MOD trades at $227.88, down 0.64% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.71 exceeding expectations. Revenue reached $2.58B in 2025, though net income margin is modest at 3.82%. Recent news includes institutional buying and executive appointments, while technical support sits near $221.
Analyst consensus is bullish with a $328.80 price target, but high P/E of 101.48 suggests premium valuation. Risks include margin pressure from supply chain challenges and competitive threats in data center cooling. The stock offers growth potential if margin expansion continues, but investors face volatility from technical weakness and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Modine Manufacturing Company
Modine Manufacturing Company is a global leader in thermal management technology and solutions. The company engineers, manufactures, and markets heat transfer products for a wide range of applications across the automotive, commercial, industrial, and HVAC (heating, ventilation, and air conditioning) markets. Modine's products include engine cooling systems, heat exchangers, and ventilation systems, providing critical thermal solutions for vehicles, data centers, and various equipment worldwide.
Read more on MOD →
